Tuygan Goker, the President of TRPHARM, has expressed his views on R&D, innovation and biosimilarization acceleration in the pharmaceutical industry.
Tuygan Goker, the president of TRPHARM which is one of the leading companies of the pharmaceutical industry, shared their mission and the innovative goals that they propound and sectoral evaluations. “We support change through high-tech R & D and production, and we focus on becoming a leading healthcare company rather than a follow-up company,” Goker said, “Our top priority is to successfully complete our production and clinical programs; and to provide the innovative products to the usage of doctors in the fields of oncology, immunology, and rare diseases. Our targets for 2023 are to increase the national and abroad direct investments, and to strengthen competent laboratories, and to increase the number of high quality products and to contribute to Turkey’s developing economy. We are planning to establish one of the leading biotechnology production facilities in Turkey through our biotechnology production facility in Cerkezkoy that was established in 2016. Our facility is designed in a way that can manufacture at high capacity in order to meet the drug demands of Turkey, Eurasia, Middle East and African countries.
R&D does not recognize the Rule
Tuygan Goker, who stated that the R&D activities in Turkey should be accelerated, suggested that “a full-fledged presidency should be established in order to provide private service and guidance to entrepreneurial entities and institutions investing in this sector.” Thus, Goker continued: “Round-table negotiations, in which the different stakeholders of the sector, especially the industry, the public and the universities, struggle for the same purpose, can be realized through the FDA style.” R&D do not know any restrictions, rules, and bureaucracy, and there is no R&D at the place where control begins, and liberation is necessary. The issue called as “R&D” is creativity and discovery, and “R” and “D” are not to be confused with each other. Development; it is a field that proceeds more systematically and in which the countries came from behind adapted themselves quickly and could obtain the outcomes.
Research is a medium that requires more creativity and has no boundaries. Our country has progressed a bit further in terms of development. But we have to proceed a lot in terms of research. ”
Turkish Signature in Biological Molecule Study
“The essential role of the pharmaceutical industry is not only to produce pharmaceuticals but also to create innovative values that can sometimes lead to prolongation of life, sometimes quality of life, and sometimes even a healthy life, and this crucial field plays a critical role in the development of particular countries. Pharmaceutical sector is an industry that takes place within the first five of the world. On the other hand, it is a sector with specific entry barriers and capital requirements due to the high costs and the risk of failure. Development of a single innovative drug takes 10-15 years, and it is realized with a cost of 1.5 to 2 billion dollars together with the unsuccessful trials.
This is a known fact that the time span and the costs incurred are in an upward trend. Therefore, when we examine the world; we see that the big players of the industry are consolidated in developed markets. The US alone makes up almost half of the market. In fact, almost 80 percent of the R&D studies done in the global pharmaceutical sector is carried out by the USA alone, and most of the rest is carried out by the EU countries. The vast majority of the value added in pharmaceuticals is in R&D. Production, marketing and sales activities complement the added value created by R&D. “On the other hand, Goker emphasized TRPHARM as a “start-up” and they are located as one of the first examples among existing companies.
Tuygan Goker, President of TRPHARM
Goker, who gave the message that “the things we do today are for the patients to have a healthier future, starting from scratch, we have come to this point with a very elaborate team”, explains the studies they have made actual and planned with the following words: “In the first stage, in the first five years we thought what we will do.
We have applications for bio-similar, we started the clinical program. On the other hand, we started our original molecular clinical programs. In Phase 1 we have a molecule that is a candidate for the familial Mediterranean fever. In our R & D Strategies, biologic drugs and the molecule named RPH104 come to the forefront.
In Turkey, we want to develop bio-similar from one side and original drugs, starting from Phase 1, on the other side. We carried out the study of “First in Human” of first patented molecule, a biotechnological original named RPH104, in Turkey. Strategic incentive, without sacrificing quality, biotechnology product development and production and by this way contribution to the country’s economy is another of our priorities.
We plan to conduct a study on such a project in Turkey regarding Behcet’s disease. We are involved in oncology especially with regard to bio-similar. However, we also want to focus on more diverse diseases. I think of Alzheimer’s, Parkinson’s, depression and CNS diseases. ”